Ipsen S.A. Stock
The community is currently still undecided about Ipsen S.A. with 2 Buy predictions and 0 Sell predictions.
With a target price of €93.00 there is a positive potential of 30.894% for Ipsen S.A. compared to the current price of €71.05.
Pros and Cons of Ipsen S.A. in the next few years
Performance of Ipsen S.A. vs. its peers
|BioMarin Pharmaceutical Inc.||0.710%||3.186%||-4.868%||-13.418%||-1.598%||-6.784%||-9.308%|
Other discussions about Ipsen S.A. StockNew thread Forum
ESMO 2020: Cabometyx® (cabozantinib) in Combination With Opdivo® (nivolumab) Demonstrates Significant Survival Benefits in Patients With Advanced Renal Cell Carcinoma in Pivotal Phase III CheckMate -9ER Trial
Ipsen (Euronext: IPN; ADR: IPSEY) today announced the first presentation of results from the pivotal Phase III CheckMate -9ER trial, in which Cabometyx® (cabozantinib) in
Ipsen to Present Results From MOVE, the First Global Phase III Trial in Fibrodysplasia Ossificans Progressiva (FOP), at ASBMR 2020 Annual Meeting
Ipsen (Euronext: IPN; ADR: IPSEY) today announced results from the MOVE trial, the first and only multicenter Phase III study in fibrodysplasia ossificans progressiva (FOP), to be presented during